Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing?

J Drugs Dermatol. 2006 Oct;5(9):903-4.


Acrodermatitis continua of Hallopeau (ACH) is a rare disease. Little is known about its etiology or relative effectiveness of the various therapeutic approaches. However, in the literature a pattern seems to be developing on successfully treated patients using biologic therapies. Here, we further emphasize the potential breakthrough presented by the novel immune based therapies. This report consists of a case of etanercept responsive ACH along with a brief review of the literature.

Publication types

  • Case Reports

MeSH terms

  • Acrodermatitis / diagnosis
  • Acrodermatitis / drug therapy*
  • Acrodermatitis / pathology
  • Administration, Cutaneous
  • Aged
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Desoximetasone / administration & dosage
  • Desoximetasone / therapeutic use*
  • Diagnosis, Differential
  • Drug Therapy, Combination
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Male
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Recombinant Fusion Proteins / therapeutic use*
  • Tumor Necrosis Factor-alpha*


  • Anti-Inflammatory Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • Tumor Necrosis Factor-alpha
  • Desoximetasone
  • Etanercept